These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
162 related articles for article (PubMed ID: 22056148)
1. Results of a pilot program to improve phosphorus outcomes in hemodialysis patients. Mayne TJ; Benner D; Ricketts K; Burgess M; Wilson S; Poole L; Smyth M; Colson C; Krishnan M J Ren Nutr; 2012 Sep; 22(5):472-9. PubMed ID: 22056148 [TBL] [Abstract][Full Text] [Related]
2. The Kidney Disease Outcomes Quality Initiative (K/DOQI) Guideline for Bone Metabolism and Disease in CKD: association with mortality in dialysis patients. Noordzij M; Korevaar JC; Boeschoten EW; Dekker FW; Bos WJ; Krediet RT; Am J Kidney Dis; 2005 Nov; 46(5):925-32. PubMed ID: 16253734 [TBL] [Abstract][Full Text] [Related]
3. Abnormal mineral metabolism and mortality in hemodialysis patients with secondary hyperparathyroidism: evidence from marginal structural models used to adjust for time-dependent confounding. Fukagawa M; Kido R; Komaba H; Onishi Y; Yamaguchi T; Hasegawa T; Kurita N; Fukuma S; Akizawa T; Fukuhara S Am J Kidney Dis; 2014 Jun; 63(6):979-87. PubMed ID: 24119541 [TBL] [Abstract][Full Text] [Related]
4. Effect of a dietitian-managed bone algorithm on serum phosphorus level in maintenance hemodialysis patients. Blair D; Byham-Gray L; Sweet SJ; Denmark R; Parrott JS; Lewis E; McCaffrey S; Thomson S J Ren Nutr; 2013 Mar; 23(2):98-105.e2. PubMed ID: 22800689 [TBL] [Abstract][Full Text] [Related]
5. A long-term, open-label extension study on the safety of treatment with lanthanum carbonate, a new phosphate binder, in patients receiving hemodialysis. Finn WF; Joy MS; Curr Med Res Opin; 2005 May; 21(5):657-64. PubMed ID: 15969865 [TBL] [Abstract][Full Text] [Related]
6. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)]. Lorenzo Sellares V; Torregrosa V Nefrologia; 2008; 28 Suppl 3():67-78. PubMed ID: 19018742 [TBL] [Abstract][Full Text] [Related]
7. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS). Tentori F; Blayney MJ; Albert JM; Gillespie BW; Kerr PG; Bommer J; Young EW; Akizawa T; Akiba T; Pisoni RL; Robinson BM; Port FK Am J Kidney Dis; 2008 Sep; 52(3):519-30. PubMed ID: 18514987 [TBL] [Abstract][Full Text] [Related]
8. Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice--the ECHO observational study. Ureña P; Jacobson SH; Zitt E; Vervloet M; Malberti F; Ashman N; Leavey S; Rix M; Os I; Saha H; Ryba M; Bencova V; Baños A; Zani V; Fouque D Nephrol Dial Transplant; 2009 Sep; 24(9):2852-9. PubMed ID: 19369690 [TBL] [Abstract][Full Text] [Related]
9. Intravenous alfacalcidol once versus twice or thrice weekly in hemodialysis patients. Alghareeb A; Sabry A; Bawadekji H; Alsaran K Ther Apher Dial; 2013 Feb; 17(1):30-4. PubMed ID: 23379490 [TBL] [Abstract][Full Text] [Related]
10. Lanthanum carbonate provides control of phosphorus levels in patients new to phosphate binder therapy and patients changed from other phosphate binders. Noto L J Ren Nutr; 2011 May; 21(3):277-82. PubMed ID: 20598905 [TBL] [Abstract][Full Text] [Related]
11. Adherence to K/DOQI practice guidelines for bone metabolism and disease. Hoy T; Fisher M; Barber B; Borker R; Stolshek B; Goodman W Am J Manag Care; 2007 Nov; 13(11):620-5. PubMed ID: 17988187 [TBL] [Abstract][Full Text] [Related]
12. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel Study Group. Slatopolsky EA; Burke SK; Dillon MA Kidney Int; 1999 Jan; 55(1):299-307. PubMed ID: 9893140 [TBL] [Abstract][Full Text] [Related]
13. Daily oral 25-hydroxycholecalciferol supplementation for vitamin D deficiency in haemodialysis patients: effects on mineral metabolism and bone markers. Jean G; Terrat JC; Vanel T; Hurot JM; Lorriaux C; Mayor B; Chazot C Nephrol Dial Transplant; 2008 Nov; 23(11):3670-6. PubMed ID: 18579534 [TBL] [Abstract][Full Text] [Related]
14. Effects of switching from calcium carbonate to lanthanum carbonate on bone mineral metabolism in hemodialysis patients. Manabe R; Fukami K; Ando R; Sakai K; Kusumoto T; Hazama T; Adachi T; Kaida Y; Nakayama Y; Ueda S; Kohno K; Wada Y; Yamagishi S; Okuda S Ther Apher Dial; 2013 Apr; 17 Suppl 1():35-40. PubMed ID: 23586511 [TBL] [Abstract][Full Text] [Related]
16. Consequences of the implementation of K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease in a population of patients on chronic hemodialysis. Arenas MD; Alvarez-Ude F; Torregrosa V; Gil MT; Carretón MA; Moledous A; Nuñez C; Devesa R; Albiach B J Nephrol; 2007; 20(4):453-61. PubMed ID: 17879212 [TBL] [Abstract][Full Text] [Related]
17. Association of Parameters of Mineral Bone Disorder with Mortality in Patients on Hemodialysis according to Level of Residual Kidney Function. Wang M; Obi Y; Streja E; Rhee CM; Lau WL; Chen J; Hao C; Hamano T; Kovesdy CP; Kalantar-Zadeh K Clin J Am Soc Nephrol; 2017 Jul; 12(7):1118-1127. PubMed ID: 28487345 [TBL] [Abstract][Full Text] [Related]
18. Mineral bone disorder and its management among hemodialysis patients in the Gulf Cooperation Council: Initial findings from the dialysis outcomes and practice patterns study (2012-2015). Al Salmi I; AlRukhaimi M; AlSahow A; Shaheen FA; Al-Ghamdi SM; AlAli F; AlGhareeb S; Al Maimani Y; AlGhonaim M; Bieber B; Tentori F; Pisoni RL; Saudi J Kidney Dis Transpl; 2016 Nov; 27(6 Suppl 1):62-80. PubMed ID: 27991480 [TBL] [Abstract][Full Text] [Related]
19. Control of parathyroid function in patients with a short history of hemodialysis. Nishi H; Sato T; Kurihara T; Kurosawa T; Fukagawa M Ther Apher Dial; 2005 Feb; 9(1):39-43. PubMed ID: 15828904 [TBL] [Abstract][Full Text] [Related]
20. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management. Ogata H; Koiwa F; Shishido K; Kinugasa E Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]